By Brazil Stock Guide – Oncoclínicas do Brasil Serviços Médicos S.A. (B3: ONCO3) approved on October 8 a capital increase of up to R$2.0 billion (US$370 million) through the private issuance of up to 666.7 million new common shares at R$3.00 per share. The transaction also includes subscription warrants on a one-to-one basis, granting investors the right to acquire an additional share in the future.
The operation may be partially ratified, provided that at least R$1 billion is subscribed. Shareholders also approved an increase in the company’s authorized capital from 1.3 billion to 3.5 billion shares, paving the way for future issuances. The issue price was set at a 4.5% discount to the market closing on September 15. Shares may be paid in cash or through debt instruments, including debentures and other credits owed by Oncoclínicas or its subsidiaries.
“The capital increase is a necessary and convenient measure to strengthen the financial structure and expand liquidity,” the company said in its statement. Management added that the funds will reinforce cash and liquidity, reduce leverage, and “ensure greater financial balance and long-term sustainability.”
Each shareholder will be entitled to subscribe to 1.03 new shares for each share held as of October 8. The stock began trading ex-rights on October 9, and subscription rights will trade until November 4 under the code ONCO1. The plan also allows bondholders to use their debenture credits to pay for new shares, effectively converting debt into equity and easing balance-sheet pressure.
The move is part of Oncoclínicas’ effort to rebalance its capital structure after an expansion cycle driven by acquisitions. By strengthening liquidity and reducing financial costs, the company aims to maintain investments in technology and oncology centers across Brazil.
Recently, CEO Bruno Ferrari acknowledged missteps in the company’s push into hospital projects and said Oncoclínicas will refocus on its traditional strengths — oncology clinics and partnerships with hospitals. Smaller and underperforming units will be closed, while resources will be redirected to major centers to improve operational efficiency.
The “back to basics” plan runs parallel to the R$2 billion capital increase, which is expected to cut leverage from 4.4x to about 2x and restore financial flexibility. Ferrari told investors he anticipates visible improvements in third-quarter results and dismissed speculation about his resignation, emphasizing that he retains full support from the board.
Leave a Reply